<table>
<thead>
<tr>
<th><strong>LLS MISSION AND PURPOSE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The mission of The Leukemia &amp; Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.</strong></td>
</tr>
<tr>
<td><strong>We fund RESEARCH to advance lifesaving treatments.</strong></td>
</tr>
<tr>
<td><strong>We provide patients, survivors, caregivers, families and healthcare professionals with hope, guidance, EDUCATION and SUPPORT.</strong></td>
</tr>
<tr>
<td><strong>We drive ADVOCACY for policies that protect patient access to lifesaving treatment.</strong></td>
</tr>
</tbody>
</table>

| **Approximately every 3 minutes** someone in the U.S. is diagnosed with blood cancer |
| **Nearly 1.4 million** people in the U.S. are living with or in remission from leukemia, lymphoma or myeloma |
| **About 30 percent of** blood cancer patients still do not survive five years after diagnosis |
| **About 40 percent** of all pediatric cancers are blood cancers |
LLS MISSION INVESTMENT IS SUPPORTED BY MULTIPLE REVENUE SOURCES

OUR IMPACT

- Invested nearly $1.3 billion in research and development worldwide since founded in 1949
- Helped advance 52 of 60 FDA approved blood cancer drugs
- Supported >93,000 patients since inception
- Responded to 20,000 inquiries in 2019
LLS GLOBAL RESEARCH AND DEVELOPMENT FOCUS

Research and development programs and clinical trials using LLS resources

**DISCOVER**
Research Grant Programs

**DEVELOP**
Beat AML Initiative

**COMMERCIALIZ**
Patient Education, Access & Advocacy

---

**Therapy Acceleration Program®**

---

**Academic Grants**
~$50 Million/yr over past 20 years at over 80 institutions with >4,000 projects total

**PedAL**
Global precision medicine trial focused on pediatric relapsed leukemia

**Therapy Acceleration Program®**
~$10 Million/yr venture philanthropy initiative funding >70 portfolio projects since 2007

**Beat AML® Master Clinical Trial**
LLS Sponsored precision medicine trial

---

LEUKEMIA & LYMPHOMA SOCIETY
LLS THERAPY ACCELERATION PROGRAM (TAP)
Venture philanthropy funding to support novel therapies

Established in 2007

>$130 Million invested to date
- Biotech: >$95 Million
- Institutions: ~$35 Million
- >70 financings of companies and assets
- >20 assets currently in active development

4 Approved Therapies to Benefit Patients
- Vyxeos (AML) - FDA
- Yescarta (DLBCL, tFL, PMBCL) - FDA
- Elzonris (BPDCN) - FDA
- Copiktra (PTCL) - NCCN

ROI Focus:
- FDA Approvals
- Assets in clinical development
- Strategic transactions & financing for portfolio companies
- Financial ROI to LLS

www.LLS.org/tap

New + Incremental Investments – 2021/2022
LLS TAP SCIENTIFIC & BUSINESS LEADERSHIP

Lore Gruenbaum, PhD
VP, TAP
- 20 years drug discovery & clinical development
- VP, Gotham Therapeutics; Exec Dir, Applied Biomath
- Biomarker Head, Virology, Roche; Group Leader, BI
- Yale postdoctoral work, principal investigator and collaborator on several SBIR grants

Lee Greenberger, PhD
SVP, Chief Scientific Officer
- 20 years big pharma and biotech
- Oversight responsibility for >$50 M annual research budget
- Advanced > 10 oncology therapeutics into the clinic
- Search & due diligence experience with big pharma

Javeed Froozan, MBA, BS
VP, Business Development
- 25 years biopharma and health technology value creation
- Sr. Dir, Emergent BioSolutions, Multiple start-ups/exits, 2 IPOs
- Business lead on EBS-Trubion M&A transaction. Alliance Manager for Pfizer relationship
- Strategic Investments, M&A, Business Development, Asset Management, and Economic Development

Blaine Robinson, PhD
Executive Director, TAP
- 15 years research & clinical development in blood cancer
- Search & Diligence on 100+ projects
- Scientific lead for over 20 TAP projects including Constellation, Kymera, Ryvu & most recently Abintus, Caribou & Immune-Onc
- Pediatric leukemia researcher, Children’s Hospital of Philadelphia

Jun Xu, PhD
Executive Director – TAP Lead
- 20 years oncology/immunology drug discovery/development
- Search & Diligence on 100+ projects
- Scientific lead for over 20 TAP projects including multiple high impact ones, such as Stemline, Kite, argenX, Forty Seven & most recently Carisma

Therapy Acceleration Program Committee: [https://www.lls.org/therapy-acceleration-program/oversight](https://www.lls.org/therapy-acceleration-program/oversight)
TAP GOALS & INVESTMENT STRATEGY
Accelerate innovative blood cancer therapies and generate ROI for LLS mission

Focus on high-value assets:
- Existing and emerging populations with high unmet needs
- Gaps in current and emerging treatment landscape
- Innovative science, first-in-class assets
- First-in-heme/onc and registration trials
- Strong intellectual property, management, and finances
TAP BIOTECH ACCELERATION MODEL

2 PATHS TO CO-INVEST WITH INVESTORS AND VENTURE PHILANTHROPIES

Strategic
- Range of Investment: $2 Million to $10 Million
- Presentation to TAP Committee
- Typically, 3-6 months to reach TAP Committee

Opportunistic
- Target Investment: $500,000
- LLS TAP team briefs TAP Committee Chair
- Transaction completion in 1-3 months
TAP ACTIVELY COLLABORATES WITH PARTNER COMPANIES

Investment Side Letter & Research Advisory Committee

Key features of LLS TAP Investment Side Letter

- Cites LLS Mission focus and company’s focus and assets in blood cancer
- Investment amount on same terms and conditions as other investors, and use of proceeds (less detail for public companies)
- Exclusion of fees on LLS proceeds to investment banks and other intermediaries (via waiver, decreased total load, or refund to company)
- Information & observer rights (private firms)
- Research Advisory Committee (RAC) structure for recurring meetings between TAP team and company to discuss corporate and program progress – Company retains control of program
- Company participation in LLS events, publication review, and evaluate providing research materials to PI’s.

Side letter captures the mission-driven collaborative nature of the relationship between LLS TAP and the partner companies
TAP VALUE ADD TO BIOTECH COMPANIES

TAP-funded companies benefit from LLS blood cancer insight

- Deep knowledge of indications and rapidly changing SoC
- Unique scientific, clinical, and drug development expertise
- Patient access services to enable understanding of patient needs
- Immediate access to extensive KOL network
- Pharmaceutical, biotech, and research institution partner connections
- Regulatory insight through LLS initiatives (Beat AML Master Clinical Trial®)

TAP record of success provides scientific & investment credibility, and visibility enabling companies to raise additional funds.
TAP PORTFOLIO THERAPEUTIC PLATFORMS FUNDED (2007-2022)

Portfolio is aligned with strong industry focus on Targeted Therapy and reflects growing interest in Cell and IO Therapies in blood cancer

73 Projects

- Targeted Therapy
- Novel IO/antibody
- Cell Therapy
- Epigenetic
- Fusion
- Vaccine
- ADC
- Novel Chemo
- Bispecific
- Protein Degrader
- RNA

>$130 Million
TAP PORTFOLIO INVESTMENTS IN ACUTE MYELOID LEUKEMIA (AML)
TAP team understands & successfully invests in complex therapeutic areas

High Unmet Medical Need
- 72,000 newly diagnosed in 8 major markets (2019)
- >10,000 deaths per year in US
- Complex, heterogeneous disease
- Ineffective long-term disease control with current therapies
- Elderly patients not fit for chemo
- Growing use of targeted therapies and combinations

Significant Market Opportunity
- Global AML market $1.4 Billion (2019)
- CAGR 13.6% (projected to 2029)
# TAP Portfolio Assets in Development

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Target/Modality</th>
<th>Indications</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 2 Reg / Phase 3</th>
<th>Regulatory Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magrolimab + Azacitidine</td>
<td>CD47 antibody</td>
<td>MDS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">FortySeven</a></td>
</tr>
<tr>
<td>AFM13</td>
<td>CD30/CD16A bispecific engager</td>
<td>PTCL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Affimed</a></td>
</tr>
<tr>
<td>Pelabresib + Ruxolitinib</td>
<td>BET small molecule</td>
<td>MPN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Constellation</a></td>
</tr>
<tr>
<td>Magrolimab + Rituximab</td>
<td>CD47 antibody</td>
<td>DLBCL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">FortySeven</a></td>
</tr>
<tr>
<td>Cusaturutamab + Azacitidine</td>
<td>CD70 antibody</td>
<td>AML</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">argenx</a></td>
</tr>
<tr>
<td>Ziltromib</td>
<td>Menin small molecule</td>
<td>AML: NPM1 mutant &amp; KMT2A rearranged</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STRO-001</td>
<td>CD74 antibody drug conjugate</td>
<td>NHL/MM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mavorixafor + Ibrutinib</td>
<td>CXC4 small molecule</td>
<td>CXCR4 &amp; MYD88 double mutant Waldenström's</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IO-202</td>
<td>LILRB4 antibody</td>
<td>AML/CML</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Kura</a></td>
</tr>
<tr>
<td>RVU120</td>
<td>CDK8/9 small molecule</td>
<td>AML/MDS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Sutro Biopharma</a></td>
</tr>
<tr>
<td>ICT01</td>
<td>BTN3A antibody</td>
<td>heme malignancies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">ImCheck therapeutics</a></td>
</tr>
<tr>
<td>PVX-410 + ACY-241 +/- Len</td>
<td>XBP1/CD13/CS1 vaccine</td>
<td>Smoldering myeloma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">OncoPep</a></td>
</tr>
<tr>
<td>NEXI-001</td>
<td>T cell therapy</td>
<td>AML</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">NexImmune</a></td>
</tr>
<tr>
<td>NEXI-002</td>
<td>T cell therapy</td>
<td>MM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">NexImmune</a></td>
</tr>
<tr>
<td>BTX-1188</td>
<td>GSP1T1 + INZFI/3 degrader</td>
<td>AML/NHL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Biotheryx</a></td>
</tr>
<tr>
<td>CB-010</td>
<td>CD19/PD1 KO allogeneic CAR</td>
<td>NHL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">CARIBOU BIOSCIENCES</a></td>
</tr>
<tr>
<td>KT-333</td>
<td>STAT3 degrader</td>
<td>PTCL/CTCL/LGL-L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Kymera</a></td>
</tr>
<tr>
<td>KT-413</td>
<td>IRAKIMI degrader</td>
<td>MYD88 mutant DLBCL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bexmarilimab</td>
<td>Clever-1 antibody</td>
<td>AML/MDS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Immunitas therapeutics</a></td>
</tr>
<tr>
<td>IMT-009</td>
<td>CD161 antibody</td>
<td>NHL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Faron</a></td>
</tr>
<tr>
<td>TBD</td>
<td>in vivo CAR-X</td>
<td>TBD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Abintus</a></td>
</tr>
<tr>
<td>TBD</td>
<td>CAR macrophage</td>
<td>TBD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Carisma Therapeutics</a></td>
</tr>
</tbody>
</table>

---

1: Acquired by Gilead  
2: Acquired by Morphosys  
3: Licensed from University of Michigan

Updated July 2022
TAP FUNDED ASSETS CREATE VALUE

TAP portfolio partners have had successful M&A, collaboration and licensing transactions

<table>
<thead>
<tr>
<th>Kite Pharma</th>
<th>GILEAD</th>
</tr>
</thead>
<tbody>
<tr>
<td>FORTY SEVEN</td>
<td></td>
</tr>
<tr>
<td>Constellation Pharmaceuticals</td>
<td>morphosys</td>
</tr>
<tr>
<td>Celator Pharmaceuticals</td>
<td>Jazz Pharmaceuticals</td>
</tr>
<tr>
<td>Stemline</td>
<td>MENARINI group</td>
</tr>
<tr>
<td>Kiadis Pharma</td>
<td>SANOFI</td>
</tr>
<tr>
<td>Acetylon Pharmaceuticals</td>
<td>Celgene</td>
</tr>
<tr>
<td>Epizyme</td>
<td>WindMIL Therapeutics</td>
</tr>
<tr>
<td>AVILA</td>
<td></td>
</tr>
<tr>
<td>JOHNS HOPKINS MEDICINE</td>
<td></td>
</tr>
<tr>
<td>University of Michigan Medical School</td>
<td>Kura Oncology</td>
</tr>
</tbody>
</table>

Transactions

>$20 Billion
### TAP PORTFOLIO COMPANY WITH ASSETS IN ACTIVE BLOOD CANCER DEVELOPMENT

<table>
<thead>
<tr>
<th>Equity since TAP Funding*</th>
<th>TAP Portfolio Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;$1 Billion</td>
<td>argenx Epizyme</td>
</tr>
<tr>
<td>&gt;$500 Million</td>
<td>Constellation¹</td>
</tr>
<tr>
<td></td>
<td>Kura²</td>
</tr>
<tr>
<td></td>
<td>Kymera²</td>
</tr>
<tr>
<td>$250-$500 Million</td>
<td>Caribou²</td>
</tr>
<tr>
<td></td>
<td>Curis</td>
</tr>
<tr>
<td></td>
<td>Forty Seven³</td>
</tr>
<tr>
<td></td>
<td>Sutro</td>
</tr>
<tr>
<td>$100-$250 Million</td>
<td>Affimed</td>
</tr>
<tr>
<td></td>
<td>BioTheryx²</td>
</tr>
<tr>
<td></td>
<td>ImCheck²</td>
</tr>
<tr>
<td></td>
<td>Neximmune²</td>
</tr>
<tr>
<td></td>
<td>X4²</td>
</tr>
<tr>
<td>$50-$100 Million</td>
<td>Carisma²</td>
</tr>
<tr>
<td></td>
<td>Immune-Onc²</td>
</tr>
<tr>
<td></td>
<td>Immunitas²</td>
</tr>
<tr>
<td></td>
<td>Ryvu</td>
</tr>
<tr>
<td></td>
<td>WindMIL²</td>
</tr>
<tr>
<td>&lt;$50 Million</td>
<td>Abintus²</td>
</tr>
<tr>
<td></td>
<td>Faron²</td>
</tr>
<tr>
<td></td>
<td>Indaptus²</td>
</tr>
<tr>
<td></td>
<td>OncoPep²</td>
</tr>
</tbody>
</table>

1: LLS asset funding (07/2021 M&A by MorphoSys); 2: LLS equity; 3: LLS equity participation plus asset funding (05/2020 M&A by Gilead)
KEY POINTS

LLS TAP has established record of success
- Targeting unmet medical needs
- Leading to FDA approvals of life changing therapeutics
- Creating value for patients, companies and ROI for the LLS mission

LLS would like to expand the reach & impact of the TAP program
- Leverage its unique expertise in novel collaborations
- Attract more companies and investors to blood cancer indications
- Expand TAP capacity to support the most promising assets

For more information, contact:
Lore Gruenbaum, PhD 914.821.8361 | Lore.Gruenbaum@LLS.org
Javeed Froozan, MBA 914.821.8817 | Javeed.Froozan@LLS.org
TAP
SUCCESS STORIES
TAP SUCCESS: NOVEL LIPOSOMAL CYTOTOXIC THERAPY

*Vyxeos*® is the first FDA-approved treatment for two types of poor-prognosis AML (2017)

**ACQUIRED BY JAZZ PHARMA FOR $1.5 BILLION IN 2016**

**LLS TAP PROVIDED:**

**$9.15 MILLION ASSET FUNDING**

**ROI: $25.3 MILLION**

Five-year final results of a phase 3 study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML

*J. Lancet et al., ASCO 2020*
TAP SUCCESS: CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY

Yescarta® is the first FDA-approved CAR-T Therapy in NHL (2017)

LLS has invested > $80 M in Cellular Immunotherapy since 1998

ACQUIRED BY GILEAD FOR $11.9 BILLION IN 2017

LLS TAP PROVIDED:

$2.5 MILLION ASSET FUNDING

ROI: $6.25 MILLION

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicenter, Ph 1-2 trial

Locke et al. 2019. Lancet Oncology
TAP SUCCESS: NOVEL TARGETED CD123 FUSION PROTEIN

*Elzonris®* is the first approved therapy for rare blood cancer indication BPDCN (2018)

**ACQUIRED BY MENARINI GROUP FOR $677 MILLION IN 2020**

**LLS TAP PROVIDED:**

**$2.9 MILLION NET ASSET FUNDING**

**ROI: $7.25 MILLION TO DATE**

Treatment outcomes of 29 patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who received first-line treatment with tagraxofusp: Probability of overall survival

*Pemmaraju et al., 2019. NEM*
"Patients with r/r PTCL usually relapse quickly and have limited treatment options, and the data from the PRIMO trial show very promising activity and even a remarkable number of complete responses. Importantly, these responses are better than current standard of care options" said Dr. Brammer.
TAP SUCCESS: MAGROLIMAB (ANTI-CD47 ANTIBODY)

Magrolimab + Azacitidine induces high response rates in MDS and AML
Initiation of registration-enabling studies in 2020

Magrolimab blocks the ‘don’t eat me’ signal on tumor cells

ACQUIRED BY GILEAD FOR $4.9 BILLION IN 2020

LLS TAP PROVIDED:

$4.175 MILLION ASSET FUNDING

$3 MILLION EQUITY INVESTMENT

ROI: >$40 MILLION

Magrolimab blocks the ‘don’t eat me’ signal on tumor cells

<table>
<thead>
<tr>
<th>Best Overall Response</th>
<th>1L MDS N=33</th>
<th>1L AML N=25</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORR</td>
<td>30 (91%)</td>
<td>16 (64%)</td>
</tr>
<tr>
<td>CR</td>
<td>14 (42%)</td>
<td>10 (40%)</td>
</tr>
<tr>
<td>MI/S</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FR</td>
<td>1 (3%)</td>
<td>1 (4%)</td>
</tr>
<tr>
<td>MLFS/marrow CR</td>
<td>8 (24%)</td>
<td>1 (4%)</td>
</tr>
<tr>
<td>Hematologic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Improvement (HI)</td>
<td>7 (21%)</td>
<td>NA</td>
</tr>
<tr>
<td>SD</td>
<td>3 (9%)</td>
<td>8 (32%)</td>
</tr>
<tr>
<td>PD</td>
<td>0</td>
<td>1 (4%)</td>
</tr>
</tbody>
</table>

- Magrolimab + AZA induces a 91% ORR (42% CR) in MDS and 64% ORR (56% CR/CI) in AML
- Responses deepened over time with a 56% 6-month CR rate in MDS patients (assessed in all patients 6 months after initial treatment)
- Median time to response is 1.9 months, more rapid than AZA alone
- Magrolimab + AZA efficacy compares favorably to AZA monotherapy (CR rate 6-17%)^1-2


LEUKEMIA & LYMPHOMA SOCIETY

22
TAP SUCCESS: KO-539 (MENIN INHIBITOR)
First-in-class inhibitor of the menin-MLL interaction in Ph1 trial for patients with relapsed/refractory AML

KO-539 Demonstrates Encouraging Early Clinical Activity

PRECLINICAL COMPOUNDS RELATED TO KO-539 LICENSED TO KURA ONCOLOGY IN 2015

LLS TAP PROVIDED:
$6.31 MILLION ASSET FUNDING TO U MICHIGAN

ROI: EQUITY: 26,000+ SHARES + $26,000+ CASH TO DATE

- Grants initially and then TAP supported preclinical development (including chemistry) of menin-MLL interaction inhibitors by Jolanta Grembecka at University of Michigan and licensing of assets to Kura Oncology in Dec 2014
- Phase 1/2a trial for R/R AML with MLL fusions/NPM1 mutations
  - First patient dosed in Sept 2019
  - Initiated expansion cohorts in July 2021

Wang et al. ASH 2020 #115
TAP SUCCESS: PELABRESIB (BET INHIBITOR)

Pelabrelib + Ruxolitinib induces high spleen volume response rates in JAK-naive myelofibrosis

Initiation of registration-enabling study in 2020

First Novel Mechanism Beyond JAK Inhibitors to Demonstrate POC in 1L MF

- Robust response rate to date in trial of > 60 1L patients
- Strong activity observed as a monotherapy and add on to ruxolitinib 2L+ patients
- Translational data and improvement in anemia supports disease-modifying potential
- Pelabrelib has been generally well-tolerated to date
- Phase 3 trial (MANIFEST-2) under way

ACQUIRED BY MORPHOSYS FOR $1.7 BILLION IN 2021

LLS TAP PROVIDED:

$7.35 MILLION ASSET FUNDING

ROI: $7.35 MILLION TO DATE
THERAPY ACCELERATION PROGRAM COMMITTEE

Casey Cunningham, MD (Chair) +
Santé Ventures

Stephen Ansell, MD, PhD
Mayo Clinic Rochester

Madhav Dhodapkar, MBBS
Emory University

Courtney DiNardo, MD
The University of Texas MD Anderson Cancer Center

Giulio Draetta, MD, PhD
The University of Texas MD Anderson Cancer Center

Christopher Flowers, MD +
The University of Texas MD Anderson Cancer Center

Patrick Fortune, PhD, MBA
Partners HealthCare Systems

Tapan Kadia, MD
The University of Texas MD Anderson Cancer Center

Laura Kaufman, PhD, DABT
Private Consultant

Ronald Levy, MD
Stanford University School of Medicine

Fred Locke, MD
Moffitt Cancer Center

Ruben Mesa, MD +
UT Health San Antonio

Vern Norviel, JD
Wilson Sonsini Goodrich & Rosati

Daniel Pollyea, MD
University of Colorado

Jim Reddoch, PhD
Royalty Pharma

Robert Rosen, JD +
Grewhawke Capital Advisors

Steven Rosen, MD
City of Hope

Robert Spiegel, MD
Spiegel Consulting LLC

Keith Stewart, MD
Princess Margaret Cancer Center

+ National Board Member
THANK YOU!

LLS Research Grants and TAP

Lee Greenberger, PhD
CSO & SVP Research

Michael Yaffe, PhD
VP of Research

Erik Nelson, PhD
Exec. Dir. Research

James Kasper, MS
Exec. Dir. Research

Orsi Giricz, PhD
Dir. Research

Lore Gruenbaum, PhD
VP of TAP

Jun Xu, PhD
Exec. Dir. TAP Lead

Blaine Robinson, PhD
Exec. Dir. TAP

Javeed Froozan, MBA
VP of BD & Alliance